GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cash And Cash Equivalents

Galapagos NV (Galapagos NV) Cash And Cash Equivalents

: $181.9 Mil (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Galapagos NV's quarterly cash and cash equivalents increased from Jun. 2023 ($106.20 Mil) to Sep. 2023 ($170.09 Mil) and increased from Sep. 2023 ($170.09 Mil) to Dec. 2023 ($181.90 Mil).

Galapagos NV's annual cash and cash equivalents declined from Dec. 2021 ($2,523.58 Mil) to Dec. 2022 ($538.26 Mil) and declined from Dec. 2022 ($538.26 Mil) to Dec. 2023 ($181.90 Mil).


Galapagos NV Cash And Cash Equivalents Historical Data

The historical data trend for Galapagos NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,068.46 2,597.55 2,523.58 538.26 181.90

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 538.26 132.91 106.20 170.09 181.90

Galapagos NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Galapagos NV  (NAS:GLPG) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Galapagos NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (Galapagos NV) Headlines